Announcement PDF ASX Announcement 12 January 2021 Change of Auditors Invion Limited (ASX:IVX) (“Invion” or the “Company”) announces that Grant Thornton Audit Pty Ltd (“Grant Thornton”) have been appointed as the Company’s Auditors with effect from today, 12 January 2021. This appointment follows the resignation of Ernst & Young and ASIC’s consent to same. The Board’s decision to change auditors was made following a consultation process, and chose Grant Thornton based on their reputation and experience, particularly with similar sized biotechnology companies to Invion. In accordance with section 327C of the Corporations Act 2001, a resolution will be tabled at the Company’s 2021 Annual General Meeting to ratify the appointment of Grant Thornton as the Company’s auditor. The Board of Directors would like to take this opportunity to thank Ernst & Young for their assistance and services to the Company to date. --ENDS-This announcement is authorised for release to the market by the Company Secretary of Invion Limited. Investor and Media enquiries: Thian Chew (Chairman) T: +61 3 9692 7222 E: investor@inviongroup.com Brendon Lau (Investor & Media Relations) T: +61 409 341 613 E: brendon@vantagepointpartners.com.au About Invion Invion is a life-science company that is leading the global research and development of PhotosoftTM technology for the treatment of a range of cancers. Invion holds the Australia and New Zealand license rights to the PhotosoftTM technology. Research and clinical trials are funded by the technology licensor, RMW Cho Group Limited, via an R&D services agreement with the Company. Invion is listed on ASX (ASX:IVX). This announcement was approved for release by the Board of Invion Limited. For further information please contact investor@inviongroup.com. About Photodynamic Therapy (PDT) Invion is developing Photosoft™ technology as an improved next generation Photodynamic Therapy. PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours and stimulates the immune system. A potential alternative to surgery, and in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes. Invion Limited ABN 76 094 730 417 Level 4, 100 Albert Road, South Melbourne, VIC, 3205, Australia P: +61 3 9692 7222 W: www.inviongroup.com